More Clarity Pharmaceuticals Ltd. news
Clarity Pharmaceuticals Ltd.ASX: CU6

First participant imaged in Phase II SAR-Bombesin trial

Oct 5, 2022 at 11:19 PM EDT · Issued by Clarity Pharmaceuticals Ltd.

Filed with ASX · Oct 5, 2022 at 11:19 PM EDT

On 6ix: 6ix.com/news/first-participant-imaged-in-phase-ii-sar-bombesin-trial

Clarity Pharmaceuticals Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Clarity Pharmaceuticals Ltd. on 6ix

Story so far

  • IND Approval by US FDA for Phase II SAR-Bombesin trialJun 6, 2022

Earlier from Clarity Pharmaceuticals

  • First participants imaged in SAR-Bombesin trialSep 13, 2022
  • Recruitment opens for Phase II trial in Prostate CancerSep 4, 2022
  • Paediatric neuroblastoma trial advances to cohort 3Aug 23, 2022
  • Imaging trial in prostate cancer opens for recruitmentAug 22, 2022
  • Application for quotation of securities - CU6Jul 5, 2022

Later from Clarity Pharmaceuticals

  • First patient treated in therapeutic prostate cancer trialOct 6, 2022
  • 50% recruitment milestone reached for prostate cancer trialOct 26, 2022
  • Corporate Presentation - Wilsons Drug and Device ConferenceOct 28, 2022
  • 50% recruitment reached for Phase II prostate cancer trialNov 1, 2022
  • Clarity Presentation -Bell Potter Healthcare Conference 2022Nov 9, 2022
All Clarity Pharmaceuticals news releases↗

Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.

Follow Clarity Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer